Novo Nordisk Receives FDA Approval For Higher Dose Of Its Weight-Loss Drug Wegovy

Novo Nordisk AS (NVO) on Thursday announced that it has received approval from the U.S. Food and Drug Administration (FDA) for a higher dose of its weight-loss drug Wegovy.

The company stated that Wegovy HD, a once-weekly injectable semaglutide at 7.2 mg, has received FDA accelerated approval based on results from the STEP UP trial program.

Novo Nordisk shares were down nearly 2% in Thursday morning’s trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.

Get updates to this story developing directly on Stocktwits.

Also See: American Rebel Shares Sink More Than 40% — What's Driving The Plunge?

For updates and corrections, email newsroom[at]stocktwits[dot]com.